HAS-BLED Score for Major Bleeding Risk
Estimates risk of major bleeding for patients on anticoagulation to help determine risk-benefit in atrial fibrillation care.
There are recommendations to use the HAS-BLED Score with the CHA2DS2-VASc Score to help determine if anticoagulation is in the best interest of a particular patient. "Major bleeding" was defined in the HAS-BLED study as "intracranial, [requiring] hospitalization, hemoglobin decrease > 2 g/L, and/or transfusion."
"HAS-BLED" is an acronym for:
- Abnormal Liver/Renal Function
- Stroke History
- Bleeding Predisposition
- Labile INRs
- "Elderly" (Age >e; 65)
- Drugs/Alcohol Usage
- Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJ, Lip GY. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest. 2010 Nov;138(5):1093-100. Epub 2010 Mar 18. PubMed PMID: 20299623.
- Lip GY, Frison L, Halperin JL, Lane DA. Comparative validation of a novel risk score for predicting bleeding risk in anticoagulated patients with atrial fibrillation: the HAS-BLED (Hypertension, Abnormal Renal/Liver Function, Stroke, Bleeding History or Predisposition, Labile INR, Elderly, Drugs/Alcohol Concomitantly) score. J Am Coll Cardiol. 2011 Jan 11;57(2):173-80. Epub 2010 Nov 24. PubMed PMID: 21111555.